ZIVO Bioscience, Inc. ZIVO
At closeOct 30, 2026, 4:00 PM EDT
- YTD
- +6.32%
- 1 year
- -35.31%
- Market cap
- 38.99M
- Revenue (ttm)
- 15.85K
- EPS (ttm)
- -2.18
- Shares out
- 1.82M
- Forward P/E
- -1.64
- YTD return
- +6.32%
- 1-year return
- -35.31%
- Volume
- 801
- Avg volume
- 521
- Open
- 8.25
- Previous close
- 8.59
- Day's range
- 8.25 – 9.25
- 52-week range
- 1.11 – 16.49
- Beta
- -0.07
- Analysts
- Buy
- Price target
- 36.00 (+289.2%)
- Earnings date
- Aug 14, 2023
2Y -12.22 (-62.76%)
Key statistics
- Enterprise value
- 2.42M
- PEG ratio
- 0.00
- Price / sales
- 150.96
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -3.34M
- Total cash
- 1.48M
- Total debt
- 1.50M
- Return on equity
- -3956.02%
- Short % of float
- 2.61%
- 50-day average
- 1.98
- 200-day average
- 11.10
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2023
Expected Aug 14, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.67 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -2.78 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.47 | — | — |
| Mar 15, 2024 | Dec 1, 2023 | 0.00 | -0.96 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 14, 2021 | Maxim Group | init | — | Buy |
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zivobioscience.com
News
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace 
ZIVO Bioscience Provides Special Letter to Shareholders 
Financial Survey: ZIVO Bioscience (NASDAQ:ZIVO) versus Finch Therapeutics Group (NASDAQ:FNCH) 
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses 
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry 
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry 
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry 
ZIVO Bioscience to Present at The Microcap Conference 2025 
ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities 
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
Your note
Sign in to keep a note on ZIVO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORNELL ALISON A | Director | Purchase | Dec 12, 2022 | 27,000 |
| MAGGIORE CHRISTOPHER D | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 12, 2023 | 179,124 |
| MASTERSON NOLA E | Director | Purchase | Dec 18, 2022 | 5,198 |
| PAYNE JOHN BERNARD | Chief Executive Officer | Purchase | Dec 18, 2022 | 9,401 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.80% | 1,023,870 | 2.48M | Jun 29, 2023 |
| Geode Capital Management, LLC | 2.61% | 272,788 | 660.15K | Jun 29, 2023 |
| Vanguard Group Inc | 1.11% | 116,330 | 281.52K | Jun 29, 2023 |
| Corecap Advisors, LLC | 0.25% | 26,166 | 65.42K | Dec 30, 2022 |
| Schechter Investment Advisors, LLC | 0.21% | 22,250 | 53.84K | Jun 29, 2023 |
| Column Capital Advisors, LLC | 0.11% | 12,000 | 29.04K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 2.55% | 266,026 | 731.57K | May 30, 2023 |
| Vanguard Total Stock Market Index Fund | 0.78% | 81,788 | 197.93K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.29% | 29,851 | 72.24K | Jun 29, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,401 | 9.35K | May 30, 2023 |